Request for Nominations of Candidates To Serve on the Clinical Laboratory Improvement Advisory Committee (CLIAC), 12454-12455 [2017-04103]

Download as PDF 12454 Federal Register / Vol. 82, No. 41 / Friday, March 3, 2017 / Notices explained in FTC Rule 4.9(c).11 Your comment will be kept confidential only if the FTC General Counsel grants your request in accordance with the law and the public interest. Once your comment is posted, as legally required by FTC Rule 4.9(b), we cannot redact or remove your comment from the FTC’s public record, including the FTC’s Web site, unless you submit a confidentiality request that meets the requirements for such treatment under FTC Rule 4.9(c), and the General Counsel grants that request in accordance with the law and the public interest, as explained above. Postal mail addressed to the Commission is subject to delay due to heightened security screening. As a result, we encourage you to submit your comments online. To make sure that the Commission considers your online comment, you must file it at https:// ftcpublic.commentworks.com/ftc/ rbprulepra, by following the instructions on the web-based form. When this Notice appears at http:// www.regulations.gov/#!home, you also may file a comment through that Web site. If you file your comment on paper, write ‘‘RBP Rule, PRA Comment, P145403,’’ on your comment and on the envelope, and mail or deliver it to the following address: Federal Trade Commission, Office of the Secretary, 600 Pennsylvania Avenue NW., Suite CC–5610 (Annex J), Washington, DC 20580, or deliver your comment to the following address: Federal Trade Commission, Office of the Secretary, Constitution Center, 400 7th Street SW., 5th Floor, Suite 5610 (Annex J), Washington, DC 20024. If possible, submit your paper comment to the Commission by courier or overnight service. The FTC Act and other laws that the Commission administers permit the collection of public comments to consider and use in this proceeding as appropriate. The Commission will consider all timely and responsive public comments that it receives on or before May 2, 2017. For information on the Commission’s privacy policy, including routine uses permitted by the Privacy Act, see http://www.ftc.gov/ftc/ privacy.htm. mstockstill on DSK3G9T082PROD with NOTICES David C. Shonka, Acting General Counsel. [FR Doc. 2017–04117 Filed 3–2–17; 8:45 am] BILLING CODE 6750–01–P 11 In particular, the written request for confidential treatment that accompanies the comment must include the factual and legal basis for the request, and must identify the specific portions of the comment to be withheld from the public record. See FTC Rule 4.9(c), 16 CFR 4.9(c). VerDate Sep<11>2014 16:42 Mar 02, 2017 Jkt 241001 DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Request for Nominations of Candidates To Serve on the Clinical Laboratory Improvement Advisory Committee (CLIAC) The Centers for Disease Control and Prevention (CDC) is soliciting nominations for membership on CLIAC. CLIAC provides scientific and technical advice and guidance to the Secretary, Department of Health and Human Services (HHS); the Assistant Secretary for Health, HHS; the Director, Centers for Disease Control and Prevention (CDC); the Commissioner, Food and Drug Administration (FDA); and the Administrator, Centers for Medicare & Medicaid Services (CMS). The advice and guidance pertain to general issues related to improvement in clinical laboratory quality and laboratory medicine. In addition, the Committee provides advice and guidance on specific questions related to possible revision of the CLIA standards. Examples include providing guidance on studies designed to improve safety, effectiveness, efficiency, timeliness, equity, and patient-centeredness of laboratory services; revisions to the standards under which clinical laboratories are regulated; the impact of proposed revisions to the standards on medical and laboratory practice; and the modification of the standards and provision of non-regulatory guidelines to accommodate technological advances, such as new test methods, the electronic transmission of laboratory information, and mechanisms to improve the integration of public health and clinical laboratory practices. CLIAC consists of 20 members including the Chair, represents a diverse membership across laboratory specialties, professional roles (laboratory management, technical specialists, physicians, nurses) and practice settings (academic, clinical, public health), and includes a consumer representative. In addition, the Committee includes three ex officio members (or designees), including the Director, CDC; the Administrator, CMS; and the Commissioner, FDA. A nonvoting representative from the Advanced Medical Technology Association (AdvaMed) serves as the industry liaison. The Designated Federal Official (DFO) or their designee and the Executive Secretary are present at all meetings to ensure meetings are within applicable statutory, regulatory and PO 00000 Frm 00028 Fmt 4703 Sfmt 4703 HHS General Administration manual directives. Request for Candidates: Nominations are being sought for individuals who have expertise and qualifications necessary to contribute to accomplishing CLIAC’s objectives. Nominees will be selected by the HHS Secretary or designee from authorities knowledgeable across the fields of microbiology (including bacteriology, mycobacteriology, mycology, parasitology, and virology), immunology (including histocompatibility), chemistry, hematology, pathology (including histopathology and cytology), or genetic testing (including cytogenetics); representatives from the fields of medical technology, public health, and clinical practice; and consumer representatives. Members may be invited to serve for terms of up to four years. The U.S. Department of Health and Human Services policy stipulates that Committee membership be balanced in terms of points of view represented, and the committee’s function. Appointments shall be made without discrimination on the basis of age, race, ethnicity, gender, sexual orientation, gender identity, HIV status, disability, and cultural, religious, or socioeconomic status. Nominees must be U.S. citizens, and cannot be full-time employees of the U.S. Government. Current participation on federal workgroups or prior experience serving on a federal advisory committee does not disqualify a candidate; however, HHS policy is to avoid excessive individual service on advisory committees and multiple committee memberships. Committee members are Special Government Employees, requiring the filing of financial disclosure reports at the beginning and annually during their terms. CDC reviews potential candidates for CLIAC membership each year, and provides a slate of nominees for consideration to the Secretary of HHS for final selection. HHS notifies selected candidates of their appointment near the start of the term in July, or as soon as the HHS selection process is completed. Note that the need for different expertise and individuals to maintain the appropriate demographic balance varies from year to year and a candidate who is not selected in one year may be reconsidered in a subsequent year. Candidates should submit the following items to be considered for nomination. The deadline for receipt of materials for the 2018 term is May 1, 2017: • Current curriculum vitae, including complete contact information (name, E:\FR\FM\03MRN1.SGM 03MRN1 Federal Register / Vol. 82, No. 41 / Friday, March 3, 2017 / Notices affiliation, mailing address, telephone number, email address). • Letter(s) of recommendation from person(s) not employed by the U.S. Department of Health and Human Services. Contact Person for More Information: Nancy Anderson, Chief, Laboratory Practice Standards Branch, Division of Laboratory Systems, Center for Surveillance, Epidemiology and Laboratory Services, Office of Public Health Scientific Services, Centers for Disease Control and Prevention, 1600 Clifton Road, NE., Mailstop F–11, Atlanta, Georgia 30329–4018; telephone (404) 498–2741; or via email at NAnderson@cdc.gov. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities for both the Centers for Disease Control and Prevention, and the Agency for Toxic Substances and Disease Registry. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. Management Analysis and Services Office, CDC, pursuant to Public Law 92– 463. Matters for Discussion: The meeting will include the initial review, discussion, and evaluation of applications received in response to ‘‘Cooperative Research Agreements to the World Trade Center Health Program (U01)’’, PAR 16–098. Contact Person for More Information: Nina Turner, Ph.D., Scientific Review Officer, CDC/NIOSH, 1095 Willowdale Road, Mailstop G905, Morgantown, West Virginia 26505, Telephone: (304) 285–5975. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. 2017–04102 Filed 3–2–17; 8:45 am] BILLING CODE 4163–18–P [FR Doc. 2017–04103 Filed 3–2–17; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Centers for Disease Control and Prevention mstockstill on DSK3G9T082PROD with NOTICES Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces a meeting for the initial review of applications in response to Funding Opportunity Announcement (FOA), PAR 16–098 Cooperative Research Agreements to the World Trade Center Health Program (U01). Times and Dates: 8:00 a.m.–5:00 p.m., EDT, March 28, 2017 (Closed) 8:00 a.m.–12:00 p.m., EDT, March 29, 2017(Closed) Place: Courtyard Marriott Decatur Downtown/Emory, 130 Clairemont Avenue, Decatur, Georgia 30030, Telephone: (404)371–0204. Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c) (4) and (6), Title 5 U.S.C., and the Determination of the Director, VerDate Sep<11>2014 16:42 Mar 02, 2017 Jkt 241001 Request for Nominations of Candidates To Serve on the Mine Safety and Health Research Advisory Committee (MSHRAC), National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention (CDC), Department of Health and Human Services The CDC is soliciting nominations for possible membership on the Mine Safety and Health Research Advisory Committee (MSHRAC), National Institute for Occupational Safety and Health (NIOSH). The MSHRAC consists of 13 experts in fields related to mining safety and health. The members are selected by the Secretary of the U.S. Department of Health and Human Services (HHS). The committee advises the NIOSH Director on mining safety and health research and prevention programs. The committee also provides advice on standards of scientific excellence, current needs in the field of mining safety and health, and the applicability and dissemination of research findings. This advice may take the form of reports PO 00000 Frm 00029 Fmt 4703 Sfmt 4703 12455 or verbal communications to the NIOSH Director during MSHRAC meetings. Nominations are being sought for individuals who have expertise and qualifications necessary to contribute to the accomplishment of the committee’s mission. Nominees will be selected based on expertise in the field of mining safety and health, such as mining engineering, industrial hygiene, occupational safety and health engineering, chemistry, safety and health education, ergonomics, epidemiology, statistics, and psychology. Members may be invited to serve for terms of up to four years. The U.S. Department of Health and Human Services policy stipulates that Committee membership be balanced in terms of points of view represented, and the committee’s function. Appointments shall be made without discrimination on the basis of age, race, ethnicity, gender, sexual orientation, gender identity, HIV status, disability, and cultural, religious, or socioeconomic status. Nominees must be U.S. citizens, and cannot be full-time employees of the U.S. Government. Current participation on federal workgroups or prior experience serving on a federal advisory committee does not disqualify a candidate; however, HHS policy is to avoid excessive individual service on advisory committees and multiple committee memberships. Committee members are Special Government Employees, requiring the filing of financial disclosure reports at the beginning and annually during their terms. CDC reviews potential candidates for the MSHRAC membership each year, and provides a slate of nominees for consideration to the Secretary of HHS for final selection. Candidates should submit the following items: • Current curriculum vitae, including complete contact information (name, affiliation, mailing address, telephone number, email address) • A letter of recommendation stating the qualifications of the candidate. Nomination materials must be postmarked by April 30, 2017, and sent to: Jeffrey H. Welsh, Designated Federal Officer for MSHRAC, NIOSH, CDC, 626 Cochrans Mill Road, Pittsburgh, PA 15236, telephone (412) 386–4040. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register Notices pertaining to announcements of meetings and other committee management activities, for the Centers for Disease Control and Prevention and E:\FR\FM\03MRN1.SGM 03MRN1

Agencies

[Federal Register Volume 82, Number 41 (Friday, March 3, 2017)]
[Notices]
[Pages 12454-12455]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-04103]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Request for Nominations of Candidates To Serve on the Clinical 
Laboratory Improvement Advisory Committee (CLIAC)

    The Centers for Disease Control and Prevention (CDC) is soliciting 
nominations for membership on CLIAC. CLIAC provides scientific and 
technical advice and guidance to the Secretary, Department of Health 
and Human Services (HHS); the Assistant Secretary for Health, HHS; the 
Director, Centers for Disease Control and Prevention (CDC); the 
Commissioner, Food and Drug Administration (FDA); and the 
Administrator, Centers for Medicare & Medicaid Services (CMS). The 
advice and guidance pertain to general issues related to improvement in 
clinical laboratory quality and laboratory medicine. In addition, the 
Committee provides advice and guidance on specific questions related to 
possible revision of the CLIA standards. Examples include providing 
guidance on studies designed to improve safety, effectiveness, 
efficiency, timeliness, equity, and patient-centeredness of laboratory 
services; revisions to the standards under which clinical laboratories 
are regulated; the impact of proposed revisions to the standards on 
medical and laboratory practice; and the modification of the standards 
and provision of non-regulatory guidelines to accommodate technological 
advances, such as new test methods, the electronic transmission of 
laboratory information, and mechanisms to improve the integration of 
public health and clinical laboratory practices.
    CLIAC consists of 20 members including the Chair, represents a 
diverse membership across laboratory specialties, professional roles 
(laboratory management, technical specialists, physicians, nurses) and 
practice settings (academic, clinical, public health), and includes a 
consumer representative. In addition, the Committee includes three ex 
officio members (or designees), including the Director, CDC; the 
Administrator, CMS; and the Commissioner, FDA. A nonvoting 
representative from the Advanced Medical Technology Association 
(AdvaMed) serves as the industry liaison. The Designated Federal 
Official (DFO) or their designee and the Executive Secretary are 
present at all meetings to ensure meetings are within applicable 
statutory, regulatory and HHS General Administration manual directives.
    Request for Candidates: Nominations are being sought for 
individuals who have expertise and qualifications necessary to 
contribute to accomplishing CLIAC's objectives. Nominees will be 
selected by the HHS Secretary or designee from authorities 
knowledgeable across the fields of microbiology (including 
bacteriology, mycobacteriology, mycology, parasitology, and virology), 
immunology (including histocompatibility), chemistry, hematology, 
pathology (including histopathology and cytology), or genetic testing 
(including cytogenetics); representatives from the fields of medical 
technology, public health, and clinical practice; and consumer 
representatives. Members may be invited to serve for terms of up to 
four years.
    The U.S. Department of Health and Human Services policy stipulates 
that Committee membership be balanced in terms of points of view 
represented, and the committee's function. Appointments shall be made 
without discrimination on the basis of age, race, ethnicity, gender, 
sexual orientation, gender identity, HIV status, disability, and 
cultural, religious, or socioeconomic status. Nominees must be U.S. 
citizens, and cannot be full-time employees of the U.S. Government. 
Current participation on federal workgroups or prior experience serving 
on a federal advisory committee does not disqualify a candidate; 
however, HHS policy is to avoid excessive individual service on 
advisory committees and multiple committee memberships. Committee 
members are Special Government Employees, requiring the filing of 
financial disclosure reports at the beginning and annually during their 
terms. CDC reviews potential candidates for CLIAC membership each year, 
and provides a slate of nominees for consideration to the Secretary of 
HHS for final selection. HHS notifies selected candidates of their 
appointment near the start of the term in July, or as soon as the HHS 
selection process is completed. Note that the need for different 
expertise and individuals to maintain the appropriate demographic 
balance varies from year to year and a candidate who is not selected in 
one year may be reconsidered in a subsequent year.
    Candidates should submit the following items to be considered for 
nomination. The deadline for receipt of materials for the 2018 term is 
May 1, 2017:
     Current curriculum vitae, including complete contact 
information (name,

[[Page 12455]]

affiliation, mailing address, telephone number, email address).
     Letter(s) of recommendation from person(s) not employed by 
the U.S. Department of Health and Human Services.
    Contact Person for More Information: Nancy Anderson, Chief, 
Laboratory Practice Standards Branch, Division of Laboratory Systems, 
Center for Surveillance, Epidemiology and Laboratory Services, Office 
of Public Health Scientific Services, Centers for Disease Control and 
Prevention, 1600 Clifton Road, NE., Mailstop F-11, Atlanta, Georgia 
30329-4018; telephone (404) 498-2741; or via email at 
NAnderson@cdc.gov.
    The Director, Management Analysis and Services Office, has been 
delegated the authority to sign Federal Register notices pertaining to 
announcements of meetings and other committee management activities for 
both the Centers for Disease Control and Prevention, and the Agency for 
Toxic Substances and Disease Registry.

Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease 
Control and Prevention.
[FR Doc. 2017-04103 Filed 3-2-17; 8:45 am]
 BILLING CODE 4163-18-P